At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 5 enrolled
Drug / intervention
tumor lysate-pulsed autologous dendritic cell vaccine +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Clinical Trial Evaluating Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen for the Treatment of Low-grade Glioma
In Brief
A Phase 2 clinical trial evaluating tumor lysate-pulsed autologous dendritic cell vaccine and laboratory biomarker analysis for Adult Diffuse Astrocytoma and 4 related conditions. Completed, enrolled 5 participants across 1 site.
Detailed Summary
The primary purpose of this phase II clinical trial is to determine the safety and effect on survival of patients autologous dendritic cells pulsed with autologous tumor lysate as a treatment for low-grade glioma patients. Other goals of this study are to determine if the vaccine can cause an immune response against patients' cancer cells and slow the growth of their brain tumors
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdult Diffuse Astrocytoma, Adult Mixed Glioma, Adult Oligodendroglioma, Recurrent Adult Brain Tumor, Adult Oligoastrocytoma
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
Enrollment StartJan 2012
First PostedJul 2012
Primary CompletionMay 2016
TodayJul 2026
First PostedJul 9, 2012
Enrollment StartJan 10, 2012
Primary CompletionMay 13, 2016
TodayJul 2, 2026
Enrollment to primary: 4.3 yearsPosted 14.0 years ago
Interventions
tumor lysate-pulsed autologous dendritic cell vaccinebiological
Given ID
laboratory biomarker analysisother
Correlative studies